基于MRI验证2018 FIGO分期在局部晚期宫颈癌根治性放疗患者中的应用
本研究纳入677例经盆腔MRI诊断并接受根治性(放)化疗的局部晚期宫颈癌患者,按2009和2018 FIGO分期比较生存结局。中位随访77.9个月,2018分期IIIC1/IIIC2生存因T分期不同而异,列线图预测PFS优于FIGO分期。
要点
- 2018 FIGO IIIC期患者生存异质,取决于局部肿瘤T分期。
- 列线图预测PFS的AUC为0.718,优于FIGO 2009和2018。
- 组织学、肿瘤大小、淋巴结转移等为独立预后因素。
核心结论
- 2018 FIGO分期修订后III期宫颈癌患者生存结局存在异质性。
- 列线图可辅助FIGO系统预测根治性放疗后PFS。
研究设计与样本
- 回顾性分析677例1992-2018年经盆腔MRI诊断并接受根治性(放)化疗的局部晚期宫颈癌患者。
- 按2009和2018 FIGO分期分类并比较生存,开发列线图预测PFS。
主要发现
- 盆腔淋巴结阳性331例(48.9%),腹主动脉旁淋巴结阳性78例(11.5%)。
- 中位随访77.9个月,2009 FIGO IB、IIA、IIB、IIIA、IIIB、IVA的5年PFS分别为83.5%、65.2%、71.0%、60.6%、37.6%、38.9%。
- 2018 FIGO IB、IIA、IIB、IIIA、IIIB、IIIC1、IIIC2、IVA的5年PFS分别为88.9%、60.0%、73.8%、66.7%、36.3%、68.9%、43.6%、38.9%。
- IIIC1期中T1、T2、T3的5年PFS分别为80.3%、73.9%、45.5%;IIIC2期中分别为100%、44.9%、23.4%。
- Cox回归显示组织学、肿瘤大小、淋巴结转移、FIGO 2009和治疗方式是独立预后因素。
临床怎么用
- 对局部晚期宫颈癌患者,可结合列线图个体化预测PFS。
- III期患者需关注局部肿瘤T分期对预后的影响。
局限性
- 单中心回顾性研究,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate the revised 2018 International Federation of Gynecologic and Obstetrics (FIGO) staging system in patients who underwent diagnostic magnetic resonance imaging (MRI) and radiotherapy (RT) for locally advanced cervix cancer. METHODS: We analyzed 677 patients who were diagnosed with pelvic MRI and treated with definitive (chemo-)RT for locally advanced cervix cancer (stage IB2/IIA2-IVA or N+) between 1992 and 2018. Patients were classified according to 2009 and 2018 FIGO staging, and survival outcomes were compared. We developed a nomogram to improve prediction of progression-free survival (PFS). RESULTS: Pelvic and paraaortic lymph nodes were positive in 331 (48.9%) and 78 (11.5%) patients, respectively. At a median follow-up of 77.9 months, the 5-year PFS was 83.5%, 65.2%, 71.0%, 60.6%, 37.6% and 38.9% for IB, IIA, IIB, IIIA, IIIB and IVA according to FIGO 2009 and 88.9%, 60.0%, 73.8%, 66.7%, 36.3%, 68.9%, 43.6%, and 38.9% for IB, IIA, IIB, IIIA, IIIB, IIIC1, IIIC2, and IVA according to FIGO 2018, respectively. Survival of stage IIIC cervix cancer depended on the local extent of the tumor: the 5-year PFS of T1, T2, and T3 stages were 80.3%, 73.9%, and 45.5% for IIIC1 and 100%, 44.9%, and 23.4% for IIIC2. Histology, tumor size, node metastasis, FIGO 2009, and treatment modality were independent prognostic factors in the Cox regression analysis, and the nomogram incorporating these factors outperformed FIGO 2009 and FIGO 2018 (AUC 0.718 vs. 0.616 vs. 0.594). CONCLUSIONS: FIGO 2018 revision was associated with heterogenous outcomes among stage III cervix cancer patients. Our nomogram can assist the FIGO system in predicting PFS after definitive RT.
引用
- Kim J, Cho Y, Kim N, et al. Magnetic resonance imaging-based validation of the 2018 FIGO staging system in patients treated with definitive radiotherapy for locally advanced cervix cancer. Gynecol Oncol. 2020. PMID: 33358037. doi:10.1016/j.ygyno.2020.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。